Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. (PRPH) generates a steady flow of company news across biotech, genomics, and consumer health. Its press releases and regulatory disclosures cover developments in molecular diagnostics, whole genome sequencing, OTC dietary supplements, capital markets activity, and strategic initiatives. For investors and followers of PRPH, this news stream provides insight into how the company is advancing its programs and managing its capital structure.
A major news theme for ProPhase is the BE-Smart Esophageal Cancer Test. Company announcements describe peer-reviewed validation studies conducted with Mayo Clinic, publication in leading gastroenterology journals, and plans for commercialization and clinical integration. Updates often detail BE-Smart’s performance metrics, its role in Barrett’s Esophagus risk stratification, and steps toward broader adoption and reimbursement discussions.
Another recurring topic is genomics and Nebula Genomics. ProPhase’s news highlights its whole genome sequencing offerings and the positioning of Nebula Genomics as a consumer genomics platform with a large and diverse DNA dataset. Releases also discuss related consumer health initiatives, including DNA Complete and DNA Expand product lines, within the company’s genomics and wellness strategy.
Capital structure and financing updates are also prominent in PRPH news. Recent items include information on senior secured convertible notes and warrants registered via an S-1, an at-the-market sales agreement, a 1-for-10 reverse stock split to address listing requirements, and shareholder communications about trading activity, convertible debt conversions, and the transition from Nasdaq to the OTC market. These disclosures explain how ProPhase is addressing liquidity, managing dilution, and aligning its share structure with strategic goals.
Strategic and legal developments appear as well, such as a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., the Crown Medical Collections receivables recovery initiative, and updates on legal matters disclosed in Form 8-K filings. For readers tracking PRPH, this news page aggregates these diverse updates in one place, making it easier to follow the company’s diagnostics, genomics, consumer health, and corporate actions over time.
ProPhase Labs (OTC: PRPH) has begun a potential sale or strategic partnership process for BE-Smart™, a CLIA-certified, CAP-accredited LDT for esophageal cancer risk stratification, and is advancing its Crown Medical Collections recovery initiative.
ProPhase completed a clinical/commercial dossier, has contacted more than 70 potential partners, cited a Mayo Clinic pilot showing high sensitivity, and estimates an addressable opportunity up to $14 billion. The company now believes > 60% of Crown Medical claims are underpaid (not denied), and reports rising interest in recovery-based, non-recourse financing that would be repaid from recoveries only.
ProPhase Labs (OTC: PRPH) invites investors to a live webinar on February 3, 2026 at 4:15 p.m. ET hosted by RedChip Companies featuring Chairman & CEO Ted Karkus. The presentation will review recent milestones including full U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test.
Other topics include a strategic initiative to recover more than $50 million in COVID-19 receivables, Nebula Genomics and planned commercialization of BE-Smart™, plus expansion of DNA Complete® and DNA Expand™ product lines.
ProPhase Labs (OTC: PRPH) provided an update on its Crown Medical Collections initiative for legacy COVID-19 testing receivables held by its lab subsidiaries in Chapter 11.
Crown Medical is engaged with 250+ insurance payors, with ~50 matters in advanced settlement posture and anticipated resolutions in 30–90 days (initial settlements expected Q1 2026). Labs billed ~$300M during COVID-19, with ~$150M unpaid or underpaid; aggregate net cash recoveries after fees could exceed $50M, subject to negotiation and court processes.
ProPhase Labs (OTC: PRPH) announced that its common stock was approved and uplisted from the Pink Sheets to the OTC market on January 22, 2026. The company said it expects the coming weeks to be an important inflection point and highlighted continued momentum in its Crown Medical collections initiative. ProPhase said it will provide a near-term operational update on Crown Medical and a strategic update on its BE-Smart® Esophageal Cancer Test. Management reiterated focus on executing core businesses and strengthening the company’s financial position to drive long-term shareholder value.
ProPhase Labs (OTC: PRPH) provided an update on recent capital‑structure activity, stock volatility, and underlying asset value on January 5, 2026. Management said >$3.3 million of convertible debt principal has converted (from $3.8 million issued), leaving less than $500,000 unconverted. Conversions occurred at a floor price of ~$0.76 per share, which the company says is above current trading levels, reducing near‑term conversion selling risk. The company completed a 1‑for‑10 reverse split and moved from Nasdaq to the OTC market; management said these technical events, plus accelerated conversions, drove temporary selling pressure but did not change the intrinsic value of operating assets.
Management emphasized debt reduction, a stronger balance sheet, and ongoing work on Crown Medical receivables, the BE‑Smart esophageal cancer diagnostic, and Nebula Genomics / DNA Complete.
ProPhase Labs (NASDAQ: PRPH) and Advanced Biological Laboratories entered a non-binding LOI on Dec 19, 2025 proposing a reverse merger that would make ABL majority owner (~76%) of the combined company.
The LOI is preliminary and subject to due diligence, definitive agreements, regulatory and Nasdaq approvals, and other conditions. A preliminary valuation framework implies a legacy ProPhase enterprise value of up to $30 million. ProPhase may declare a special cash dividend up to $10 million to shareholders of record (separate from the merged company). Crown Medical Collections receivables are expected to be carved out for current shareholders with anticipated collections of ≈$50 million net. The combined company would assume only agreed liabilities, currently contemplated to include $5 million of ProPhase indebtedness.
ABL Diagnostics reports that its controlling shareholder ABL S.A. and ProPhase Labs (Nasdaq: PRPH) have signed a non-binding letter of intent for a proposed reverse merger under which ABL would become the majority owner of the combined company.
The LOI is preliminary, creates no obligation to close, and is subject to due diligence, definitive agreements, regulatory approvals, and Nasdaq listing requirements. The parties target an indicative 60–90 day timeframe to execute definitive agreements. ABL S.A.’s control over ABL Diagnostics is unchanged and the proposal does not trigger the mandatory offer threshold based on available information.
The transaction may require ProPhase shareholder approval in the U.S. if a change of control occurs or if an issuance reaches 20% or more. The release is treated as inside information and will be archived for at least 5 years.
ProPhase Labs (NASDAQ: PRPH) will host an exclusive investor webinar on December 1, 2025 at 4:15 p.m. ET, hosted by RedChip Companies and featuring Chairman & CEO Ted Karkus.
The presentation will review ProPhase’s portfolio across molecular diagnostics, genomics, and consumer health, recent milestones including U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test, and a stated $7–14 billion addressable market for that test. Management will discuss a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, a streamlined cost structure, and the consumer genomics business Nebula Genomics with a large, diverse DNA dataset.
Planned near-term catalysts noted include commercialization of BE-Smart™ and expansion of DNA Complete® and DNA Expand™ product lines; a live Q&A follows. Registration is free via the RedChip webinar link.
ProPhase Labs (NASDAQ: PRPH) reported third-quarter 2025 results and announced strategic initiatives on November 19, 2025.
Key points: Q3 revenue $0.9M vs $1.4M year‑ago; net loss $6.8M or $(0.16) per share; cash $405,000; working capital deficit $47.5M. The company is pursuing M&A discussions, a $50M+ Crown Medical collections initiative entering settlement and litigation phases, commercialization of the BE‑Smart™ esophageal cancer test following a Mayo Clinic validation publication, and says Nebula Genomics is now profitable on a pro‑forma basis.
Management will present to shareholders today, November 19, 2025 at 2:00 p.m. ET via a virtual non‑deal roadshow.
ProPhase Labs (NASDAQ: PRPH) reminds shareholders of record as of Oct 20, 2025 to vote ahead of the Special Meeting on Nov 24, 2025 at 10:00 a.m. ET (in person at 273 Merrick Road, Lynbrook, NY).
Shareholders should submit votes before the proxy deadline of 11:59 p.m. ET on Nov 23, 2025. The board recommends voting FOR all proposals to enable strategic initiatives and actions to maintain Nasdaq listing compliance; the definitive proxy is available on the SEC EDGAR site.